Gemmus is a privately held biotechnology company focused on the development of innovative pharmaceutical products for the treatment of influenza and other viral infectious diseases. Using a novel, host-directed approach, we target the underlying cause of debilitating symptoms associated with influenza and ‘influenza-like-illness’ (ILI) by modulating the natural immune response to the disease. We are committed to developing “first-in-class, best-in-class” products that meet a major medical need.
Gemmus Pharma was founded in 2007 to commercialize in-licensed technology from a major pharmaceutical company. Gemmus’ lead candidate is a cardiovascular drug currently marketed in Asia that has been repurposed for use as a treatment for influenza. Gemmus has received support from the National Institute of Allergy and Infectious Disease (NIAID) and has completed a Series A round. The company has applied for and received an SBIR(NIH) and a QTDP competitive grant. Gemmus plans to file an investigational new drug (IND) application with the FDA for treatment of influenza infections in 2014.
Location: United States, California, San Francisco
Member count: 11-50
Total raised: $3.3M
Founded date: 2007
Investors 1
| Date | Name | Website |
| - | Tech Coast... | techcoasta... |
Funding Rounds 1
| Date | Series | Amount | Investors | Deal News |
| 13.05.2014 | Series B | $3.3M | - | finsmes.co... |
Mentions in press and media 5
| Date | Title | Description | Category | Author | Source |
| 13.05.2014 | Gemmus Pha... | Gemmus Pharma, a San Francisco... | funding S... | - | finsmes.co... |
| 28.06.2012 | Gemmus Pha... | Gemmus Pharma Inc., a San Fran... | funding S... | - | finsmes.co... |
| 28.06.2012 | Gemmus Pha... | SAN FRANCISCO, CA, Privately... | - | - | vcnewsdail... |
| - | Gemmus New... | San Francisco, CA, May 11, 201... | - | - | bluetreeve... |
| - | BlueTree V... | BlueTree Venture Fund, a Pitts... | - | - | bluetreeve... |